HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Export reg delayed

This article was originally published in The Rose Sheet

Executive Summary

Effective date of new notification, recordkeeping requirements for exported drugs, foods, cosmetics and devices that cannot be sold domestically postponed three months until June 19, FDA says in March 18 letters to CHPA, CTFA. Reg's provisions originally were slated to take effect March 19. Agency says it will "exercise enforcement discretion and not generally take enforcement action regarding the final rule" until publication of a Federal Register notice staying the effective date. Trade associations, Chicago law firm Sandler Travis & Rosenberg petitioned FDA for a six-month stay, arguing companies needed more time for compliance (1"The Rose Sheet" March 18, 2002, p. 7)...

You may also be interested in...



Export Recordkeeping Reg’s Implementation Period Too Short – CTFA

Three months "is too short a period of time" for firms to modify existing internal systems to meet new notification and recordkeeping requirements governing exported cosmetics, drugs and foods that cannot be sold domestically, the Cosmetic, Toiletry and Fragrance Association says in a March 12 petition to FDA

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel